Although a previous case report identified an HRAS G13D mutation in the resistance to anti-EGFR monoclonal antibodies in colorectal cancer [22], this is the first report of an HRAS-activating mutation conferring acquired resistance to AZD9291 in NSCLC. This evidence concerns the gene HRAS and non-small cell lung carcinoma.